Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Fineline Cube Jul 2, 2026
Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Fineline Cube Jul 2, 2026
Company

HutchMed Chairman Simon To Steps Down, Dr. Dan Eldar Appointed Successor

Fineline Cube May 20, 2024

HutchMed (NASDAQ: HCM, HKG: 0013) today announced a significant change in leadership with the long-serving...

Company Drug

Eisai to Support Grassroots Healthcare in China with Significant Pariet Donation

Fineline Cube May 20, 2024

Eisai (TYO: 4523), a leading Japanese pharmaceutical company, has announced its commitment to donate 100,000...

Company Drug

North China Pharmaceutical’s Ormutivimab Approved for Pediatric Use in China

Fineline Cube May 17, 2024

North China Pharmaceutical Group Corporation (SHA: 600812) has announced that it has received approval from...

Company Drug

HutchMed’s Sovleplenib Phase III Results to be Showcased at EHA 2024

Fineline Cube May 17, 2024

HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013), a biopharmaceutical company based in China, is preparing...

Company Drug

Shanghai UniCAR-Therapy’s Innovative CAR-T Therapy Targets Breakthrough Designation with IL-6 Silencing

Fineline Cube May 17, 2024

Shanghai UniCAR-Therapy Bio-Medicine Technology Co., Ltd, a leading biopharmaceutical company based in China, is on...

Company Deals

Sol-Gel Technologies Partners with Shenzhen Beimei for Twyneo Commercialization in China

Fineline Cube May 17, 2024

Israel-based dermatology specialist Sol-Gel Technologies Ltd. (NASDAQ: SLGL) has announced the signing of a licensing...

Company Deals

J&J Acquires Immune-Mediated Diseases Specialist Proteologix in a Deal Worth Up to USD 850 Million

Fineline Cube May 17, 2024

Johnson & Johnson (J&J; NYSE: JNJ), a global healthcare giant, has announced a deal to...

Policy / Regulatory

China’s Health Commission Boosts Efforts to Monitor and Respond to Drug Shortages

Fineline Cube May 17, 2024

The National Health Commission (NHC) of China has recently announced the reinforcement of national and...

Company Deals

Huaixi Medical and Beijing HumaDX Tech Join Forces to Boost In Vitro Diagnostics

Fineline Cube May 17, 2024

Huaixi Medical, a Nanjing-based specialist in flow cytometry, has entered into a strategic partnership with...

Company Drug

Bayer’s 225Ac-PSMA-Trillium Therapy Begins Early-Stage Clinical Trial for mCRPC

Fineline Cube May 17, 2024

Bayer AG (ETR: BAYN), a multinational pharmaceutical company based in Germany, has this week commenced...

Company Deals

Merck KGaA Subsidiary Teams Up with Aulos Bioscience to Test PD-L1 and Anti-IL-2 Combination

Fineline Cube May 17, 2024

Germany’s Merck KGaA (ETR: MRK) has announced that its Switzerland-based subsidiary, Ares Trading, has entered...

Company Medical Device

Chunlizhengda’s Handheld Orthopedic Robot Approved by China’s NMPA

Fineline Cube May 17, 2024

Beijing Chunlizhengda Medical Instruments Co., Ltd (HKG: 1858, SHA: 688236) has received marketing approval from...

Company

Roche Marks 30 Years in China with Commitment to Boost Investments and Local Manufacturing

Fineline Cube May 17, 2024

Roche (SWX: ROG), the Swiss pharmaceutical giant, has reaffirmed its long-term commitment to the Chinese...

Company Deals

Hengrui Pharmaceuticals Strikes Deal with Hercules CM Newco to Supply GLP-1 Products for Global Markets

Fineline Cube May 17, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has entered into...

Company Drug

Roc Rock Biotechnology Secures Ethical Approval for CAR-M Therapy in Ovarian Cancer

Fineline Cube May 16, 2024

China-based Roc Rock Biotechnology Co., Ltd. has announced that it has received ethical approval from...

Policy / Regulatory

Landmark Biosecure Act Passes US House Committee with 40-1 Vote, Eyes 2024 Enactment

Fineline Cube May 16, 2024

The US House Committee on Oversight and Accountability has completed the markup process for amendments...

Company Deals

Novo Holdings Gains Controlling Interest in Biopharma Equipment Supplier Single Use Support

Fineline Cube May 16, 2024

Novo Nordisk’s (CPH: NOVO-B) controlling shareholder, Novo Holdings, has entered into an agreement to purchase...

Company Deals

AstraZeneca and BenevolentAI Reach Milestone in Heart Failure Target Validation

Fineline Cube May 16, 2024

AstraZeneca (AZ; NASDAQ: AZN) has announced the successful experimental validation of a groundbreaking heart failure...

Company Deals

Sunho Biologics Lists on HKEX with HKD 461 Million Biotech IPO

Fineline Cube May 16, 2024

Sunho Biologics, Inc., (HKG: 2898) a clinical-stage biopharmaceutical company based in China specializing in biologic...

Company Medical Device

Lifetech Scientific’s IBS Stent Demonstrates Non-Inferiority in Phase II Trial

Fineline Cube May 16, 2024

Lifetech Scientific Corporation (HKG: 1302), a biopharmaceutical company based in China, has announced the completion...

Posts pagination

1 … 383 384 385 … 690

Recent updates

  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
  • Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy
  • Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched
  • TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations
  • TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma – Novel Non-Covalent Approach Shows Enhanced Safety Profile
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Company Drug

TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.